To assess whether the effects of statins on prostate cancer are due to HMGCR inhibition specifically or merely a consequence of lipid-lowering, we also performed Mendelian randomization analyses using genetic variants associated with other statin drug targets (PCSK9). This evidence concerns the gene PCSK9 and prostate carcinoma.